September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
5 citations
,
April 2024 in “BMC Neurology” Clinicians should recognize taste disorders and hair loss as important symptoms in myasthenia gravis patients.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
39 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” Alopecia areata significantly worsens quality of life in children, causing embarrassment and social issues.
42 citations
,
June 2019 in “Aging” 3,4,5-tri-O-caffeoylquinic acid promotes hair growth by activating the β-catenin pathway.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
December 2023 in “JEADV Clinical Practice” A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.
27 citations
,
April 2004 in “Biochemical and Biophysical Research Communications” Two new gene clusters important for hair formation were found on human chromosome 11.
1 citations
,
May 2004 in “Biochemical and Biophysical Research Communications” Two new gene clusters important for hair formation were found on human chromosome 11.
April 2024 in “Dermatology reports” Dutasteride is more effective than finasteride for hair regrowth in male and female pattern hair loss, with similar side effects.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
December 2020 in “Actas Dermo-Sifiliográficas” LLLT increases hair density and growth in AGA patients.
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
4 citations
,
January 1970 in “Journal of Bangladesh College of Physicians and Surgeons” Early diagnosis and genetic counseling are crucial for managing adrenoleukodystrophy.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
September 2024 in “Journal of the American Academy of Dermatology” Hair loss significantly affects the quality of life for Muslim American women, especially those not wearing hijab.
May 2011 in “Psychiatric News” Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
1 citations
,
January 2019 in “Indian Journal of Public Health Research and Development” Androgenic alopecia significantly affects adults' quality of life, especially in men and employed individuals.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
September 2021 in “CRC Press eBooks” Alopecia areata incognita causes sudden hair thinning, responds well to steroids, and is more common in those with genetic hair loss conditions.
4 citations
,
November 2022 in “Frontiers in Medicine” People with alopecia areata are more likely to have anxiety and depression and a lower quality of life.
1 citations
,
April 2013 in “Journal of Investigative Dermatology” December 2025 in “Chinese Medical Journal” Experts recommend starting systemic treatment for alopecia areata when the condition is severe or causes significant distress.